Market Place
Sourcing Support
Trevi Adds Clinical Development Expertise in Chronic Cough to Leadership Team
02 Apr 2024 //
PR NEWSWIRE
After $2B acquisition, GSK sends some Bellus workers packing
22 Mar 2024 //
FIERCE BIOTECH
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
16 Jun 2023 //
BUSINESSWIRE
BELLUS Health Calls Special Shareholders’ Meeting with GSK Acquisition
16 May 2023 //
BUSINESSWIRE
BELLUS Health Reports First Quarter 2023 Financial Results
12 May 2023 //
BUSINESSWIRE
BELLUS Health Announces Meeting Updates
27 Apr 2023 //
BUSINESSWIRE
GSK inks $2B Bellus buyout to challenge Merck for cough market
19 Apr 2023 //
FIERCE BIOTECH
BELLUS Announces Positive Results from PI Bioavailability Equivalence Study
05 Apr 2023 //
BUSINESSWIRE
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
21 Mar 2023 //
BUSINESSWIRE
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
BUSINESSWIRE
BELLUS Health to Present on Burden of Refractory Chronic Cough at Meeting
08 Feb 2023 //
BUSINESSWIRE
BELLUS Health Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
10 Nov 2022 //
BUSINESSWIRE
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937
10 Oct 2022 //
BUSINESSWIRE
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
06 Sep 2022 //
BUSINESSWIRE
BELLUS Health to Present Clinical Data from PIIb SOOTHE Trial of BLU-5937
22 Aug 2022 //
BUSINESSWIRE
BELLUS Health Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
BUSINESS WIRE
BELLUS Health Closes US$153M Public Offering of Common Shares
18 Jul 2022 //
BUSINESSWIRE
Why BELLUS Health Stock Fell Today
14 Jul 2022 //
FOOL
BELLUS Health Announces Pricing of US$153M Public Offering in Canada and U.S.
13 Jul 2022 //
BUSINESSWIRE
Bellus Health Announces Positive End-of-PII Meeting with FDA and its CALM PIII for BLU-5937
12 Jul 2022 //
PRESS RELEASE
BELLUS Health to Participate in the William Blair Biotech Focus Conference
05 Jul 2022 //
BUSINESSWIRE
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
13 Jun 2022 //
NASDAQ
BELLUS Health to Participate in the Jefferies Healthcare Conference
01 Jun 2022 //
BUSINESSWIRE
BELLUS Health Reports Q1 2022 Financial Results and Business Highlights
11 May 2022 //
BUSINESSWIRE
BELLUS Health to Present Late-Breaking Clinical Data from PIIb Trial of BLU-5937
02 May 2022 //
BUSINESSWIRE
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
23 Feb 2022 //
BUSINESSWIRE
Merck drug for chronic cough rejected by FDA
24 Jan 2022 //
PRESS RELEASE
BELLUS Health Closes US$200M Public Offering of Common Shares
17 Dec 2021 //
BUSINESSWIRE
BELLUS Health Announces Pricing of US$200M Public Offering
14 Dec 2021 //
BUSINESSWIRE
Bellus soars on positive mid-stage readout; fails in atopic dermatitis
14 Dec 2021 //
ENDPTS
Bellus jumps on second try for chronic cough candidate BLU-5937
13 Dec 2021 //
BUSINESSWIRE
BELLUS Health Launches Public Offering of Common Shares in Canada and U.S.
13 Dec 2021 //
BUSINESSWIRE
BELLUS Health Reports Q3 2021 Financial Results and Business Highlights
10 Nov 2021 //
BUSINESSWIRE
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough
01 Nov 2021 //
BUSINESSWIRE
BELLUS Health Completes Patient Enrollment of two Phase 2 trials
23 Sep 2021 //
BUSINESSWIRE
BELLUS Health Announces Positive Interim Analysis from PIIb Trial of BLU-5937
13 Sep 2021 //
BUSINESSWIRE
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
02 Sep 2021 //
BUSINESSWIRE
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation
23 Aug 2021 //
BUSINESSWIRE
BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT BLU-5937
14 Dec 2020 //
BUSINESSWIRE
BELLUS Health to Participate in the Evercore ISI 3rd Annual Virtual HealthCONx
24 Nov 2020 //
BUSINESSWIRE
BELLUS Health announces design for phase 2b SOOTHE trial of BLU-5937
09 Sep 2020 //
PHARMABIZ
BELLUS Health Announces its Phase 2b Trial for Refractory Chronic Cough
08 Sep 2020 //
BUSINESS WIRE
Bellus shares plummet as cough drug fails Phase 2 test
07 Jul 2020 //
BIOPHARMADIVE
BELLUS Health Announces Topline Results from its Ph2 RELIEF Trial of BLU-5937
06 Jul 2020 //
BUSINESSWIRE
BELLUS Health Announces Completion of Dosing in Ph2 RELIEF Trial BLU-5937
07 Apr 2020 //
BUSINESSWIRE
